
    
      M12-778 is a rising multiple dose, randomized, double blind, placebo controlled single center
      study. It will have 5 dose groups of 20 subjects in dose groups 1,2 and 3 and 24 subjects in
      dose groups 4 and 5; a total of 84 subjects . There will be a 7 day period between dose
      groups 1,2 and 3 to assess the safety of increasing to the next dose. Dose groups of 4 and 5
      will be run in parallel. Subjects will be confined in center for 20 days for dose groups 1,2
      and 3 and 33 days for dose groups 4 and 5.
    
  